Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
George Town, Grand Cayman, CA
SEC filing record 1 source field available
Fiscal year end
31 December
Theravance Biopharma, Inc. has filed 1,125 SEC EDGAR filings since 01 Aug 2013

SEC filing history

Showing 951-975 of 1,000 matching filings.

Per page
25
Current page
39
SC 13G/A File 005-88552

AMENDED SCHEDULE 13G

Filing date
19 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88552

NONE

Filing date
12 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88552

SC 13G/A filing

Filing date
09 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88552

SC 13G/A filing

Filing date
27 Jan 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
11 Jan 2016
Reporting date
11 Jan 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 Nov 2015
Reporting date
20 Nov 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 Nov 2015
Reporting date
20 Nov 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 Nov 2015
Reporting date
20 Nov 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 Nov 2015
Reporting date
20 Nov 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
8-A12B File 001-36033

8-A12B

Filing date
10 Nov 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
10 Nov 2015
Reporting date
10 Nov 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-88552

SCHEDULE 13G

Filing date
10 Nov 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-88552

SCHEDULE 13G

Filing date
10 Nov 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

THERAVANCE BIOPHARMA, INC. 8-K

Filing date
09 Nov 2015
Reporting date
09 Nov 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
424B5 File 333-205275

424B5

Filing date
26 Oct 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
26 Oct 2015
Reporting date
21 Oct 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Oct 2015
Reporting date
21 Oct 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 -

Filing date
23 Oct 2015
Reporting date
21 Oct 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K/A File 001-36033

8-K/A

Filing date
13 Oct 2015
Reporting date
11 Sep 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
07 Oct 2015
Reporting date
07 Oct 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-I/A File 005-88552

SC TO-I/A

Filing date
30 Sep 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-I/A File 005-88552

SC TO-I/A

Filing date
23 Sep 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-I/A File 005-88552

SC TO-I/A

Filing date
11 Sep 2015
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
11 Sep 2015
Reporting date
11 Sep 2015
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .